


MX1013

| | | |
|--------------------|--|----------------|
| Cat. No.: | HY-10397A | |
| CAS No.: | 582316-00-5 | |
| Molecular Formula: | C ₁₈ H ₂₃ FN ₂ O ₆ | |
| Molecular Weight: | 382 | |
| Target: | Caspase | |
| Pathway: | Apoptosis | |
| Storage: | Powder | -20°C 3 years |
| | In solvent | -80°C 6 months |
| | | -20°C 1 month |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (261.78 mM; Need ultrasonic)

| Concentration | Solvent | Mass | | |
|---------------------------|---------|-----------|------------|------------|
| | | 1 mg | 5 mg | 10 mg |
| Preparing Stock Solutions | 1 mM | 2.6178 mL | 13.0890 mL | 26.1780 mL |
| | 5 mM | 0.5236 mL | 2.6178 mL | 5.2356 mL |
| | 10 mM | 0.2618 mL | 1.3089 mL | 2.6178 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

MX1013 is a potent, irreversible dipeptide caspase inhibitor with antiapoptotic activity. MX1013 inhibits recombinant human caspase 3 with an IC₅₀ of 30 nM^[1].

IC₅₀ & Target

Caspase

In Vitro

MX1013 inhibits caspases 1, 3, 6, 7, 8, and 9, with IC₅₀ values ranging from 5 to 20 nM. MX1013 is selective for caspases, and is a poor inhibitor of noncaspase proteases, such as cathepsin B, calpain I, or Factor Xa (IC₅₀ values >10 μM)^[1].

MX1013 inhibits three key markers of apoptosis: the proteolytic maturation of caspase 3, the caspase-mediated cleavage of PARP, and the fragmentation of genomic DNA^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

| | |
|----------------|----------------------------|
| Cell Line: | Jurkat T-lymphocytes |
| Concentration: | 0, 0.05, 0.1, 0.25, 0.5 μM |

| | |
|------------------|---|
| Incubation Time: | Preincubated for 2 h |
| Result: | Neither caspase 3 processing nor PARP cleavage could be detected at 0.5 μ M. At concentrations of 0.05 μ M, caspase 3 processing and PARP cleavage were still markedly reduced. |

In Vivo

MX1013 is an effective antiapoptotic agent in vivo. MX1013 not only inhibits local tissue apoptosis, but also can protect animals against its lethal effects^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

| | |
|-----------------|---|
| Animal Model: | Female ND4 Swiss Webster mice (16.5-21 g) ^[1] |
| Dosage: | 0, 0.25, 1, 10 mg/kg (formulated in an aqueous vehicle containing 50 mm Tris-HCl, pH 8.0) |
| Administration: | Injected i.v. |
| Result: | The lowest dose of 0.25 mg/kg protected 66% of the mice from the lethal effects of anti-Fas antibody at the 3 h time point, and 1 and 10 mg/kg dose protected 100% of the mice at the 3 h time point. |

CUSTOMER VALIDATION

- J Infect Dis. 2024 Jan 19;jiae020.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Wu Yang, et al. MX1013, a dipeptide caspase inhibitor with potent in vivo antiapoptotic activity. Br J Pharmacol. 2003 Sep;140(2):402-12.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA